AbbVie (ABBV) Other Operating Expenses (2012 - 2026)
AbbVie (ABBV) reported Other Operating Expenses of $5.0 billion for Q1 2026, up 16.75% year-over-year from $4.2 billion in Q1 2025, and up 2186.64% on a QoQ basis from $217.0 million in Q4 2025.
AbbVie (ABBV) has 15 years of Other Operating Expenses data on file, last reported at $5.0 billion in Q1 2026.
- Quarterly Other Operating Expenses rose 16.75% year-over-year to $5.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 billion (up 22.22% YoY) and the FY2025 annual result came in at $241.0 million, up 3342.86% from the prior year.
- Other Operating Expenses climbed to $5.0 billion in Q1 2026 per ABBV's latest filing, from $217.0 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.0 billion in Q1 2026 and bottomed at -$229.0 million in Q3 2022.
- The 5-year median for Other Operating Expenses is $96.5 million (2023), against an average of $958.3 million.
- The widest annual swing landed in 2022, when Other Operating Expenses sank 145.8%; it then surged 3000.0% in 2025.
- Tracing ABBV's Other Operating Expenses over 5 years: stood at $1.0 million in 2022, then surged by 16800.0% to $169.0 million in 2023, then plunged by 95.86% to $7.0 million in 2024, then surged by 3000.0% to $217.0 million in 2025, then soared by 2186.64% to $5.0 billion in 2026.
- Per Business Quant, the three latest ABBV Other Operating Expenses figures stand at $5.0 billion (Q1 2026), $217.0 million (Q4 2025), and $24.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.96 Bn |
| Dec 31, 2025 | 217.00 Mn |
| Jun 30, 2025 | 24.00 Mn |
| Mar 31, 2025 | 4.25 Bn |
| Dec 31, 2024 | 7.00 Mn |
| Jun 30, 2023 | 169.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 1.00 Mn |
| Sep 30, 2022 | -229.00 Mn |
| Jun 30, 2022 | 172.00 Mn |
| Sep 30, 2021 | 500.00 Mn |
| Jun 30, 2021 | 68.00 Mn |
| Mar 31, 2021 | 4.40 Bn |
| Mar 31, 2020 | 1.94 Bn |
| Dec 31, 2019 | 330.00 Mn |
| Sep 30, 2019 | 1.92 Bn |
| Jun 30, 2019 | 1.91 Bn |
| Mar 31, 2019 | 1.85 Bn |
| Dec 31, 2018 | 2.32 Bn |
| Sep 30, 2018 | 1.89 Bn |
| Jun 30, 2018 | 2.43 Bn |
| Mar 31, 2018 | 2.00 Bn |
| Dec 31, 2017 | 2.59 Bn |
| Sep 30, 2017 | 1.62 Bn |
| Jun 30, 2017 | 1.54 Bn |
| Mar 31, 2017 | 1.62 Bn |
| Dec 31, 2016 | 1.59 Bn |
| Sep 30, 2016 | 1.58 Bn |
| Jun 30, 2016 | 2.56 Bn |
| Mar 31, 2016 | 1.38 Bn |
| Dec 31, 2015 | 1.48 Bn |
| Sep 30, 2015 | 2.24 Bn |
| Jun 30, 2015 | 939.00 Mn |
| Mar 31, 2015 | 1.07 Bn |
| Dec 31, 2014 | 2.03 Bn |
| Sep 30, 2014 | 1.65 Bn |
| Jun 30, 2014 | 1.13 Bn |
| Mar 31, 2014 | 1.10 Bn |
| Dec 31, 2013 | 1.33 Bn |
| Sep 30, 2013 | 1.31 Bn |
| Jun 30, 2013 | 1.12 Bn |
| Mar 31, 2013 | 1.15 Bn |
| Dec 31, 2012 | 1.29 Bn |
| Sep 30, 2012 | 1.01 Bn |
| Jun 30, 2012 | 1.18 Bn |
| Mar 31, 2012 | 1.31 Bn |